Immune thrombocytopenia, known as ITP, is classified as an autoimmune disorder by hematologists worldwide. The immune system produces antibodies that target and destroy the body’s own platelets, the tiny blood cells responsible for clotting. But calling ITP “autoimmune” only begins to describe what is happening. The disease involves more than just antibody-driven destruction; it also disrupts the bone marrow’s ability to make new platelets, and the immune dysfunction runs deeper than researchers appreciated even a decade ago.
Why ITP Qualifies as Autoimmune
In ITP, the body generates autoantibodies that latch onto proteins on the platelet surface. About three-quarters of these antibodies target one of two protein complexes found on platelets, called glycoprotein IIb/IIIa or glycoprotein Ib/IX.1PubMed. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura Once an antibody has stuck to a platelet, immune cells in the spleen recognize it as something that needs to be cleared. Splenic macrophages then engulf and destroy the tagged platelet.2PubMed Central. Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments The result is a platelet count that can drop dangerously low, sometimes far below the normal range of roughly 150,000 to 400,000 per microliter of blood.
This mechanism fits the textbook definition of autoimmunity: the immune system mistakenly identifies a normal part of the body as foreign and mounts an attack against it. ITP shares this core feature with other autoimmune conditions like lupus, rheumatoid arthritis, and autoimmune hemolytic anemia, though the specific target here is platelets rather than joints, organs, or red blood cells.
More Than Just Platelet Destruction
For a long time, ITP was understood mainly as a problem of platelets being destroyed too quickly. That picture has expanded. Researchers now know that the autoimmune attack also reaches back into the bone marrow, where platelets are made. The cells that produce platelets, called megakaryocytes, can themselves be damaged by the same autoantibodies and by immune T cells that infiltrate the marrow.3PubMed Central. Immune attack on megakaryocytes in immune thrombocytopenia Laboratory studies have shown that autoantibodies from ITP patients impair nearly every step of platelet production: the maturation of megakaryocytes, their migration within the bone marrow, and their ability to release finished platelets into the bloodstream.3PubMed Central. Immune attack on megakaryocytes in immune thrombocytopenia
T cells add another layer of damage. In people with ITP, regulatory T cells, which normally act as brakes on immune activity, are present in lower numbers than in healthy individuals.4PubMed Central. Imbalance of T Lymphocyte Subsets in Adult Immune Thrombocytopenia Meanwhile, cytotoxic T cells that directly kill target cells can attack megakaryocytes in the bone marrow, compounding the problem.5PubMed Central. T cell immune abnormalities in immune thrombocytopenia So ITP involves a two-pronged assault: platelets are destroyed faster than normal in the spleen, and the marrow’s capacity to replace them is sabotaged at the same time.
Common Symptoms
The hallmark of ITP is bleeding from the skin and mucous membranes. The medical term for this is mucocutaneous bleeding, and it shows up in recognizable ways.6PubMed. Immune thrombocytopenic purpura The most common signs include:
- Petechiae: tiny red or purple dots on the skin, often appearing on the lower legs, that result from bleeding under the surface.
- Ecchymoses: larger bruises that show up easily, sometimes without any clear injury.
- Mucosal bleeding: nosebleeds, bleeding gums, blood blisters inside the cheeks, or heavy menstrual periods in women.
A case report of a 14-year-old girl with ITP illustrates how varied the presentation can be: she came to the hospital with abdominal pain and was found to have petechiae inside her mouth, bruising on her arms and legs, and internal bleeding into her abdominal cavity, a rare but serious complication.7PubMed Central. Spontaneous Peritoneal Hemorrhage and Anemia: A Rare Case Report of Immune Thrombocytopenic Purpura Most people with ITP have milder symptoms, but severe bleeding becomes a concern when platelet counts drop very low.
How low matters a great deal. Severe bleeding is uncommon when platelets stay above 30,000 per microliter and typically occurs only when they fall below 10,000.8PubMed. Bleeding complications in immune thrombocytopenia In a study of newly diagnosed adults, platelet counts below 20,000 were a threshold for a major increase in any type of bleeding, while counts below 10,000 raised the risk of mucosal bleeding specifically. Anticoagulant use was an additional major risk factor for severe bleeding episodes.9PubMed. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults
Fatigue, the Overlooked Symptom
Many people with ITP are surprised to learn that persistent fatigue is one of the most common complaints, and one that doctors historically paid less attention to than bleeding. In studies comparing ITP patients with healthy individuals, fatigue was significantly more common: about 39% of UK patients and 22% of US patients in one study reported clinically meaningful fatigue, rates far above what would be expected in the general population.10PubMed. Fatigue in adult patients with primary immune thrombocytopenia Fatigue was associated with lower platelet counts, steroid treatment, bleeding symptoms, and other coexisting medical conditions.
The fatigue in ITP does not appear to be simply a side effect of anemia from blood loss. Researchers believe the chronic inflammation and immune dysfunction driving ITP also generate fatigue through pro-inflammatory signaling.11PubMed. Fatigue in immune thrombocytopenia An exploratory study found that while disease-specific factors like bleeding severity and platelet counts explained less than 20% of the variation in fatigue levels, broader factors like physical functioning and activity levels explained more than half. Vitamin D levels alone accounted for about 12% of the variation.12PubMed Central. Possible Targets to Reduce Fatigue in Chronic Immune Thrombocytopenia Patients – An Explorative Study That suggests fatigue in ITP is partly a consequence of living with chronic autoimmune illness and partly addressable through things like physical activity and nutritional optimization, not just platelet-directed therapy.
What Triggers ITP
In most adults, no single obvious event triggers ITP. The disease tends to develop gradually, and the initial loss of immune tolerance to platelets often cannot be traced to a specific cause. In children, however, the story is different: ITP frequently appears shortly after a viral infection, and the majority of childhood cases resolve on their own within months.
When a triggering event can be identified, infections are the most commonly implicated. The proposed mechanism is molecular mimicry: proteins on certain viruses and bacteria resemble platelet surface proteins closely enough that the immune response against the infection cross-reacts with the body’s own platelets. Infections linked to ITP through this mechanism include varicella-zoster virus, influenza, HIV, the stomach bacterium H. pylori, and SARS-CoV-2.13Autoimmunity Reviews. Immune thrombocytopenia (ITP) – could it be part of autoimmune/inflammatory syndrome induced by adjuvants (ASIA)?
Certain medications can also cause immune-mediated platelet destruction, though this is classified separately as drug-induced immune thrombocytopenia (DITP). In DITP, exposure to a specific drug triggers antibodies that react with platelet surface proteins. At least six different mechanisms have been proposed for how drugs accomplish this, and the antibody testing required to confirm the diagnosis is technically demanding and not widely available.14PubMed Central. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management Heparin-induced thrombocytopenia, or HIT, is a well-known variant where the antibodies target a different molecule entirely, platelet factor 4, and paradoxically cause clotting rather than bleeding.15Haematologica. Treatment of drug-induced immune thrombocytopenias
Genetic Susceptibility
ITP is not inherited in a straightforward way. You cannot get it from a parent the way you might inherit sickle cell disease. But genetic variation does influence who is more likely to develop ITP. Researchers have identified variations in several categories of immune-related genes, including those that code for cytokines (signaling molecules), Fc-gamma receptors (the receptors that immune cells use to recognize antibody-coated targets), and T cell co-stimulation molecules.16PubMed Central. Deciphering the genetic basis of immune thrombocytopenia: current evidence for genetic predisposition in adult ITP These genetic factors likely do not cause ITP on their own but may lower the threshold at which an environmental trigger can set off the autoimmune process.
This genetic link also helps explain why ITP sometimes clusters with other autoimmune conditions. A shared genetic background for autoimmune susceptibility means that some people are predisposed not just to ITP specifically, but to autoimmunity more broadly.
Children Versus Adults
ITP has traditionally been described as two different diseases depending on the age of the patient. In children, it often appears suddenly after an infection, causes a dramatic drop in platelets, and then resolves within weeks to months without lasting consequences. In adults, ITP tends to come on more gradually, become chronic, and prove harder to treat.17PubMed Central. Pediatric ITP: is it different from adult ITP?
The clinical differences extend beyond the platelet count itself. A large registry study found that coexisting medical conditions were present in about 30% of adults with newly diagnosed ITP, compared with only about 4% of children. Adults were more likely to have diabetes, thyroid disease, gastrointestinal problems, and high blood pressure alongside their ITP.18Haematologica. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group These comorbidities can complicate treatment and make bleeding events riskier.
ITP and Other Autoimmune Diseases
When ITP is the only autoimmune problem, it is called primary ITP. But low platelets can also be a feature of other autoimmune diseases, most commonly systemic lupus erythematosus. In that case, it is considered secondary ITP. The relationship between ITP and lupus runs both directions. ITP is a common blood-related manifestation of lupus,19PubMed. Immune thrombocytopenia in patients with systemic lupus erythematosus and a small percentage of people initially diagnosed with primary ITP later develop lupus. One follow-up study of 130 patients with primary ITP found that about 8% were eventually diagnosed with lupus, at a median of about two and a half years later.20PubMed Central. Prognostic factors for the development of systemic lupus erythematosus in patients with immune thrombocytopenia
This overlap has practical implications. If you are diagnosed with ITP, your doctor may check for signs of lupus or other autoimmune conditions, especially if you are a young woman, have additional symptoms like joint pain or skin rashes, or have positive antinuclear antibody tests. Monitoring over time matters because the autoimmune landscape can evolve.
The Diagnosis Challenge
There is no single blood test that confirms ITP. The diagnosis is reached by ruling out other causes of a low platelet count, making it what doctors call a diagnosis of exclusion. This creates room for error. In one review of 492 patients who had been given an ITP diagnosis, about 17% turned out to have something else entirely. Among the alternative diagnoses were inherited platelet disorders, lupus, an enlarged spleen causing platelet sequestration, and systemic infections, among 31 different conditions identified.21PubMed Central. Primary immune thrombocytopenia: a ‘diagnosis of exclusion’?
The high misdiagnosis rate reflects the fact that many conditions can lower platelet counts, from liver disease and bone marrow disorders to medications and nutritional deficiencies. Getting the diagnosis right is important because the treatment for ITP, which suppresses the immune system, would be inappropriate or even harmful for some of those other conditions.
The Spleen’s Central Role
The spleen is ground zero for both platelet destruction and much of the autoantibody production in ITP. Antibody-coated platelets circulating through the spleen are recognized and consumed by resident immune cells. Spleen removal (splenectomy) has been a treatment option for decades, and it remains the therapy with the highest rate of lasting response, with about 50 to 70% of patients achieving a durable improvement in platelet counts afterward.22PubMed Central. Splenectomy for immune thrombocytopenia: down but not out Still, because splenectomy carries lifelong infection risks and because newer drug therapies have improved, it is now typically reserved for patients who have not responded to other treatments.
Emerging Treatment Approaches
The deepening understanding of ITP’s autoimmune machinery has opened new treatment avenues. Traditional first-line therapy includes corticosteroids to broadly suppress immune activity and intravenous immunoglobulin to temporarily slow platelet destruction. When those fail, thrombopoietin receptor agonists can stimulate the bone marrow to produce more platelets, essentially compensating for the ongoing destruction rather than stopping it.
Newer therapies under investigation aim at more specific immune targets. These include drugs that block Bruton tyrosine kinase (a signaling protein important for antibody-producing B cells), agents that interfere with the neonatal Fc receptor (which recycles antibodies and keeps their levels high), inhibitors of splenic tyrosine kinase (which is involved in the macrophage signaling that destroys platelets), and therapies targeting complement pathways or plasma cells directly.23Thrombosis Research / Elsevier. Translating mechanisms into therapeutic strategies for immune thrombocytopenia (ITP): Lessons from clinical trials The field is active, with hundreds of clinical trials ongoing globally.
ITP in Pregnancy and Newborns
ITP complicates a small fraction of pregnancies and creates unique concerns. A pregnant person’s autoantibodies can cross the placenta and reach the fetus, causing low platelet counts in the newborn. In most cases, this autoimmune neonatal thrombocytopenia is relatively mild and resolves as the maternal antibodies clear from the baby’s system over weeks.24Neoreviews. Immune-Mediated Neonatal Thrombocytopenia It is distinct from neonatal alloimmune thrombocytopenia, where the mother’s antibodies attack the baby’s platelets because the baby inherited a platelet protein from the father that the mother’s immune system does not recognize. Alloimmune thrombocytopenia tends to be more severe and carries a higher risk of bleeding in the newborn’s brain.
The Gut-Immune Connection
An area of growing interest is the relationship between gut bacteria and ITP. Dysbiosis, an imbalance in the gut’s microbial community, has been linked to immune dysfunction in several autoimmune diseases. In ITP, researchers are investigating whether changes in the gut microbiome contribute to the immune dysregulation that drives the disease, or whether they are simply a consequence of it.25PubMed Central. The gut-immune axis in primary immune thrombocytopenia (ITP): a paradigm shifts in treatment approaches The connection is plausible because gut bacteria heavily influence how T cells develop and how immune tolerance is maintained. H. pylori, the stomach bacterium linked to ulcers, provides the clearest example: treating an active H. pylori infection improves platelet counts in a meaningful fraction of ITP patients, and this observation has already been incorporated into clinical guidelines in some countries. Whether broader manipulation of the microbiome through probiotics or other means could help remains speculative, but the gut-immune axis is one of the more promising research directions in a disease where many patients still cycle through multiple therapies without a lasting solution.